System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Silvia Grottoli is an expert in Endocrinology at University of Turin (Italy). As of September 2026, ScienceLeadR ranks Silvia Grottoli in the top 1% of experts worldwide for Pituitary Diseases, Hypothalamic Diseases and Bone Diseases, Endocrine. Silvia Grottoli has authored 261 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 2 of them ongoing. SLR score: 678 (community average: 125). How the SLR is computed.

LeadR Profile

Silvia Grottoli University of Turin Italy
678 ScienceLeadR Reputation 678

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Biochemistry - Neurology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1996 - 2026
Source: PubMed

University of Turin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 261

Citations

Citations: 5 409 1st author: 18 Last author: 70 Unique author: 4

Main journals

J Endocrinol Invest 67
Endocrine Abstracts 19
Eur J Endocrinol 19
Pituitary 18
L Endocrinologo 17

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insulin Tolerance Test in Adult GH Deficiency: An Exploratory Study Deriving BMI-Dependent Cut-Offs Using a Clinical Reference Standard.
PMID 42792742 — growth, insulin, hormones, obesity, diagnosis, overweight, insulin-like growth factor i		Biomedicines20260
GH Stimulation testing is unnecessary in patients with hypothalamic-pituitary disease, preserved pituitary function, and IGF-I SDS ≥ 0.
PMID 42493668 — research design, pituitary diseases, probability, hormones, insulin-like growth factor i		Pituitary20260
Adverse hepato-biliary-pancreatic events in acromegaly patients treated with first generation somatostatin receptor ligands.
PMID 41934517 — somatostatin, acromegaly, receptors, somatostatin, ligands		Pituitary20260
Progression of acromegalic joint and psychological complications according to sex, treatments and disease control.
PMID 41823238 — depression, radiotherapy, joint diseases, hormones, signs and symptoms, endocrine glands, acromegaly, sex, therapeutics, dopamine agonists, endocrine system diseases, suicide		Eur J Endocrinol20260
Morning cortisol and central adrenal insufficiency: new thresholds from low-dose ACTH test and second-generation assay.
PMID 41619159 — endocrinology, research design, adrenal insufficiency, immunoassay, hydrocortisone, adrenocorticotropic hormone		J Endocrinol Invest20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 4
Phase 3 3

By status:

Completed 4
Recruiting 2
Unknown 1

By type:

Interventional 5
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 3

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A randomized placebo controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with somatostatin analogs
2024-516616-24-00 — somatostatin, safety, acromegaly, octreotide		Phase 3Recruiting2025
Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction
NCT07528365 — blood, serum, urea, hyponatremia, methylenebis(chloroaniline), therapeutics, inappropriate adh syndrome, mental status and dementia tests, plasma		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS